RMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

1.40B

+8.96%

2.714

+11.71%

1.41B

+9.09%

2.767

+16.75%

1.46B

+8.22%

2.874

+12.69%

Estimates Revision

The market is revising Downward the revenue expectations for ResMed Inc. (RMD) for FY2026, with the revenue forecasts being adjusted by -0.1% over the past three months. During the same period, the stock price has changed by -6.62%.

Revenue Estimates for FY2026

Revise Downward

-0.1%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-89.83%

In Past 3 Month

Stock Price

Go Down

-6.62%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast RMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMD is 302.56 USD with a low forecast of 270.00 USD and a high forecast of 335.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

4 Hold

0 Sell

Moderate Buy

Current: 253.235

Low

270.00

Averages

302.56

High

335.00

Current: 253.235

Low

270.00

Averages

302.56

High

335.00

Baird

Outperform -> NULL

downgrade

$320 -> $300

2025-11-03

Reason

Baird

Price Target

$320 -> $300

2025-11-03

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on ResMed to $300 from $320 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q3 results.

Morgan Stanley

David Bailey

Overweight

maintain

$304 -> $305

2025-10-31

Reason

Morgan Stanley

David Bailey

Price Target

$304 -> $305

2025-10-31

maintain

Overweight

Reason

Morgan Stanley analyst David Bailey raised the firm's price target on ResMed to $305 from $304 and keeps an Overweight rating on the shares after the company delivered a "slightly better-than-expected" fiscal Q1 result, supported by "solid" operating leverage.

KeyBanc

Brett Fishbin

Overweight

maintain

$298 -> $299

2025-10-31

Reason

KeyBanc

Brett Fishbin

Price Target

$298 -> $299

2025-10-31

maintain

Overweight

Reason

KeyBanc analyst Brett Fishbin raised the firm's price target on ResMed to $299 from $298 and keeps an Overweight rating on the shares post Q1 on higher estimates. The firm viewed ResMed's Q1 2026 release as mostly positive given a modest revenue beat and sustained margin inflection. However, there were a few areas to nitpick, KeyBanc adds. More specifically, the firm notes Q1 revenue was slightly ahead of expectations, as outperformance in Devices was partially offset by Masks and Accessories and SAAS; KeyBanc was again encouraged by upside to gross margin, and it appears well on track to meet the 61%-63% guidance range for FY26; and it anticipates continued flexibility in capital allocation.

Mizuho

Outperform

NULL

downgrade

$310 -> $300

2025-10-31

Reason

Mizuho

Price Target

$310 -> $300

2025-10-31

downgrade

Outperform

NULL

Reason

Mizuho lowered the firm's price target on ResMed to $300 from $310 and keeps an Outperform rating on the shares following the fiscal Q1 report. The firm says GLP-1s are not presenting a headwind yet for ResMed while its US competition is stable.

Morgan Stanley

NULL

Overweight

maintain

$298 -> $304

2025-10-21

Reason

Morgan Stanley

Price Target

$298 -> $304

2025-10-21

maintain

NULL

Overweight

Reason

Morgan Stanley raised the firm's price target on ResMed to $304 from $298 and keeps an Overweight rating on the shares. Ahead of the company's fiscal Q1 report, the analyst notes that the firm's Q1 revenue forecast of $1.33B is 1% below the Visible Alpha consensus.

Citi

initiated

$330

2025-09-18

Reason

Citi

Price Target

$330

2025-09-18

initiated

Reason

Citi initiated coverage of ResMed's U.S. shares with a Buy rating and $330 price target. The firm believes the company's gross margin expansion potential over the next few years is being underestimated in consensus estimates. Citi sees upside to ResMed's fiscal 2027 estimates.

Valuation Metrics

The current forward P/E ratio for Resmed Inc (RMD.N) is 0.00, compared to its 5-year average forward P/E of 29.41. For a more detailed relative valuation and DCF analysis to assess Resmed Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

29.41

Current PE

0.00

Overvalued PE

38.99

Undervalued PE

19.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

22.15

Current EV/EBITDA

16.04

Overvalued EV/EBITDA

27.24

Undervalued EV/EBITDA

17.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.44

Current PS

6.45

Overvalued PS

9.03

Undervalued PS

5.86

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RMD News & Events

Events Timeline

No data

News

4.5

12-10Barron's

S&P 500 Futures Drop in Pre-Market Session; Louisiana-Pacific and GameStop Underperform

9.0

12-09NASDAQ.COM

RMD Stock Poised for Growth Following FDA Approval of AI-Driven Smart Comfort

9.0

12-08NASDAQ.COM

Resmed Receives FDA Approval for Customized Therapy Comfort Features; Will Be Branded as Smart Comfort

People Also Watch

Frequently Asked Questions

What is Resmed Inc (RMD) stock price today?

The current price of RMD is 253.235 USD — it has increased 0.38 % in the last trading day.

What is Resmed Inc (RMD)'s business?

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

What is the price predicton of RMD Stock?

What is Resmed Inc (RMD)'s revenue for the last quarter?

Resmed Inc revenue for the last quarter amounts to 1.34B USD, increased 9.07 % YoY.

What is Resmed Inc (RMD)'s earnings per share (EPS) for the last quarter?

Resmed Inc. EPS for the last quarter amounts to 2.37 USD, increased 12.32 % YoY.

What changes have occurred in the market's expectations for Resmed Inc (RMD)'s fundamentals?

How many employees does Resmed Inc (RMD). have?

Resmed Inc (RMD) has 10600 emplpoyees as of December 15 2025.

What is Resmed Inc (RMD) market cap?

Today RMD has the market capitalization of 36.82B USD.